This action will be implemented the following activities:

(a) Quality and safety of medical radiation applications
The action will include accompanying activities to:
(1) build co-operations, support and monitor medical radiations applications,
(2) develop evidence-based guidance and practical tools for quality and safety of medical ionising radiation applications,
(3) build EU dose registry for patients undergoing radiological and nuclear medicine imaging, and
(4) support to align Euratom / EU action on medical radiological diagnostic and therapeutic equipment, align Euratom / EU action on radiopharmaceuticals, and support actions for clinical audit of radiology, nuclear medicine and radiotherapy practices.

(b) Workforce education and training
The action will include activities for the:
(1) Union-wide monitoring of workforce availability, education and training;
(2) capacity building in modern radionuclide cancer diagnosis, therapy and ‘theragnostics’; and
(3) development of EU curricula and certification schemes in the quality and safety of radiology, nuclear medicine and radiotherapy.

(c) Equal access to modern medical radiation technology and interventions
The action will include:
(1) monitoring of the Union imaging and radiotherapy equipment base and the availability of modern quality and safety features;
(2) develop quality and safety criteria and optimised imaging protocols for advanced medical imaging;
(3) cover medical radiation technology, including diagnostic and therapeutic application, in national cancer plans; and
(4) improve evidence for clinical efficacy of novel cancer interventions involving ionising radiation.

Applicants should take into account the Directorate General for Energy’s calls for tenders on medical equipment and co-ordinated implementation of the legal bases for nuclear medicine and radiopharmaceuticals.

This action will ultimately benefit cancer patients and the general population in accessing radiology and nuclear medicine services in the Member States.

Participants in the action have to regularly report on the progress of the work to the Steering Group on Quality and Safety of medical applications of nuclear and radiation technology (SGQS), to be launched under the SAMIRA action plan by the end of 2021. Indicatively, this will include providing short written updates and presentations to the SGQS once every six months for the duration of the project.